|
1
|
Cohn JN, Ferrari R and Sharpe N: Cardiac
remodeling-concepts and clinical implications: A consensus paper
from an international forum on cardiac remodeling. Behalf of an
international forum on cardiac remodeling. J Am Coll Cardiol.
35:569–582. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang D, Liu HQ, Liu FY, Tang N, Guo Z, Ma
SQ, An P, Wang MY, Wu HM, Yang Z, et al: The roles of
noncardiomyocytes in cardiac remodeling. Int J Biol Sci.
16:2414–2429. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu QQ, Xiao Y, Yuan Y, Ma ZG, Liao HH, Liu
C, Zhu JX, Yang Z, Deng W and Tang QZ: Mechanisms contributing to
cardiac remodelling. Clin Sci (Lond). 131:2319–2345. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gao J, Xu W, Wang J, Wang K and Li P: The
role and molecular mechanism of non-coding RNAs in pathological
cardiac remodeling. Int J Mol Sci. 18:6082017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang LS, Liu Y, Chen Y, Ren JL, Zhang YR,
Yu YR, Jia MZ, Ning ZP, Du J, Tang CS and Qi YF: Intermedin
alleviates pathological cardiac remodeling by upregulating klotho.
Pharmacol Res. 159:1049262020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takefuji M, Wirth A, Lukasova M, Takefuji
S, Boettger T, Braun T, Althoff T, Offermanns S and Wettschureck N:
G(13)-mediated signaling pathway is required for pressure
overload-induced cardiac remodeling and heart failure. Circulation.
126:1972–1982. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McCarroll CS, He W, Foote K, Bradley A,
McGlynn K, Vidler F, Nixon C, Nather K, Fattah C, Riddell A, et al:
Runx1 deficiency protects against adverse cardiac remodeling after
myocardial infarction. Circulation. 137:57–70. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bujak M, Ren G, Kweon HJ, Dobaczewski M,
Reddy A, Taffet G, Wang XF and Frangogiannis NG: Essential role of
Smad3 in infarct healing and in the pathogenesis of cardiac
remodeling. Circulation. 116:2127–2138. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ni L, Yuan C, Chen G, Zhang C and Wu X:
SGLT2i: Beyond the glucose-lowering effect. Cardiovasc Diabetol.
19:982020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Home PD, Pocock SJ, Beck-Nielsen H, Curtis
PS, Gomis R, Hanefeld M, Jones NP, Komajda M and McMurray JJV;
RECORD Study Team, : Rosiglitazone evaluated for cardiovascular
outcomes in oral agent combination therapy for type 2 diabetes
(RECORD): A multicentre, randomised, open-label trial. Lancet.
373:2125–2135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wilcox T, De Block C, Schwartzbard AZ and
Newman JD: Diabetic agents, from metformin to SGLT2 inhibitors and
GLP1 receptor agonists: JACC focus seminar. J Am Coll Cardiol.
75:1956–1974. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zinman B, Wanner C, Lachin JM, Fitchett D,
Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ,
et al: Empagliflozin, cardiovascular outcomes, and mortality in
type 2 diabetes. N Engl J Med. 373:2117–2128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Neal B, Perkovic V, Mahaffey KW, de Zeeuw
D, Fulcher G, Erondu N, Shaw W, Law G, Desai M and Matthews DR;
CANVAS Program Collaborative Group, : Canagliflozin and
cardiovascular and renal events in type 2 diabetes. N Engl J Med.
377:644–657. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wiviott SD, Raz I, Bonaca MP, Mosenzon O,
Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et
al: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N
Engl J Med. 380:347–357. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McDonagh TA, Metra M, Adamo M, Gardner RS,
Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, et
al: 2021 ESC guidelines for the diagnosis and treatment of acute
and chronic heart failure. Eur Heart J. 42:3599–3726. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heidenreich PA, Bozkurt B, Aguilar D,
Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM,
Evers LR, et al: 2022 AHA/ACC/HFSA guideline for the management of
heart failure: A report of the American college of
cardiology/American heart association joint committee on clinical
practice guidelines. Circulation. 145:e895–e1032. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Braunwald E: Gliflozins in the management
of cardiovascular disease. N Engl J Med. 386:2024–2034. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Van Steenbergen A, Balteau M, Ginion A,
Ferté L, Battault S, Ravenstein CM, Balligand JL, Daskalopoulos EP,
Gilon P, Despa F, et al: Sodium-myoinositol cotransporter-1, SMIT1,
mediates the production of reactive oxygen species induced by
hyperglycemia in the heart. Sci Rep. 7:411662017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cowie MR and Fisher M: SGLT2 inhibitors:
Mechanisms of cardiovascular benefit beyond glycaemic control. Nat
Rev Cardiol. 17:761–772. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tripolt NJ, Kolesnik E, Pferschy PN,
Verheyen N, Ablasser K, Sailer S, Alber H, Berger R, Kaulfersch C,
Leitner K, et al: Impact of EMpagliflozin on cardiac function and
biomarkers of heart failure in patients with acute MYocardial
infarction-the EMMY trial. Am Heart J. 221:39–47. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
von Lewinski D, Tripolt NJ, Sourij H,
Pferschy PN, Oulhaj A, Alber H, Gwechenberger M, Martinek M, Seidl
S, Moertl D, et al: Ertugliflozin to reduce arrhythmic burden in
ICD/CRT patients (ERASe-trial)-a phase III study. Am Heart J.
246:152–160. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee MMY, Brooksbank KJM, Wetherall K,
Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L,
Docherty KF, et al: Effect of empagliflozin on left ventricular
volumes in patients with type 2 diabetes, or prediabetes, and heart
failure with reduced ejection fraction (SUGAR-DM-HF). Circulation.
143:516–525. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aimo A, Vergaro G, González A, Barison A,
Lupón J, Delgado V, Richards AM, de Boer RA, Thum T, Arfsten H, et
al: Cardiac remodelling-part 2: Clinical, imaging and laboratory
findings. A review from the study group on biomarkers of the heart
failure association of the European society of cardiology. Eur J
Heart Fail. 24:944–958. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Singh JSS, Fathi A, Vickneson K, Mordi I,
Mohan M, Houston JG, Pearson ER, Struthers AD and Lang CC: Research
into the effect of SGLT2 inhibition on left ventricular remodelling
in patients with heart failure and diabetes mellitus (REFORM) trial
rationale and design. Cardiovasc Diabetol. 15:972016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Santos-Gallego CG, Vargas-Delgado AP,
Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso
F, Sartori S, Roque M, Sabatel-Perez F, et al: Randomized trial of
empagliflozin in nondiabetic patients with heart failure and
reduced ejection fraction. J Am Coll Cardiol. 77:243–255. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Verma S, Mazer CD, Yan AT, Mason T, Garg
V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, et al: Effect of
empagliflozin on left ventricular mass in patients with type 2
diabetes mellitus and coronary artery disease: The EMPA-HEART
cardiolink-6 randomized clinical trial. Circulation. 140:1693–1702.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Omar M, Jensen J, Ali M, Frederiksen PH,
Kistorp C, Videbæk L, Poulsen MK, Tuxen CD, Möller S, Gustafsson F,
et al: Associations of empagliflozin with left ventricular volumes,
mass, and function in patients with heart failure and reduced
ejection fraction: A substudy of the empire HF randomized clinical
trial. JAMA Cardiol. 6:836–840. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hwang IC, Cho GY, Yoon YE, Park JJ, Park
JB, Lee SP, Kim HK, Kim YJ and Sohn DW: Different effects of SGLT2
inhibitors according to the presence and types of heart failure in
type 2 diabetic patients. Cardiovasc Diabetol. 19:692020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Soga F, Tanaka H, Tatsumi K, Mochizuki Y,
Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T and Hirata
KI: Impact of dapagliflozin on left ventricular diastolic function
of patients with type 2 diabetic mellitus with chronic heart
failure. Cardiovasc Diabetol. 17:1322018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brown AJM, Gandy S, McCrimmon R, Houston
JG, Struthers AD and Lang CC: A randomized controlled trial of
dapagliflozin on left ventricular hypertrophy in people with type
two diabetes: The DAPA-LVH trial. Eur Heart J. 41:3421–3432. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lan NSR, Yeap BB, Fegan PG, Green G,
Rankin JM and Dwivedi G: Empagliflozin and left ventricular
diastolic function following an acute coronary syndrome in patients
with type 2 diabetes. Int J Cardiovasc Imaging. 37:517–527. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
von Lewinski D, Kolesnik E, Tripolt NJ,
Pferschy PN, Benedikt M, Wallner M, Alber H, Berger R, Lichtenauer
M, Saely CH, et al: Empagliflozin in acute myocardial infarction:
The EMMY trial. Eur Heart J. 43:4421–4432. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ersbøll M, Jürgens M, Hasbak P, Kjær A,
Wolsk E, Zerahn B, Brandt-Jacobsen NH, Gæde P, Rossing P, Faber J,
et al: Effect of empagliflozin on myocardial structure and function
in patients with type 2 diabetes at high cardiovascular risk: The
SIMPLE randomized clinical trial. Int J Cardiovasc Imaging.
38:579–587. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Palmiero G, Cesaro A, Galiero R, Loffredo
G, Caturano A, Vetrano E, Rinaldi L, Salvatore T, Ruggiero R,
Rosaria Di Palo M, et al: Impact of gliflozins on cardiac
remodeling in patients with type 2 diabetes mellitus & reduced
ejection fraction heart failure: A pilot prospective study. GLISCAR
study. Diabetes Res Clin Pract. 200:1106862023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Russo V, Malvezzi Caracciolo D'Aquino M,
Caturano A, Scognamiglio G, Pezzullo E, Fabiani D, Del Giudice C,
Carbone A, Bottino R, Caso V, et al: Improvement of global
longitudinal strain and myocardial work in type 2 diabetes patients
on sodium-glucose cotransporter 2 inhibitors therapy. J Cardiovasc
Pharmacol. 82:196–200. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nagueh SF: Left ventricular diastolic
function: Understanding pathophysiology, diagnosis, and prognosis
with echocardiography. JACC Cardiovasc Imaging. 13:228–244. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ren C, Sun K, Zhang Y, Hu Y, Hu B, Zhao J,
He Z, Ding R, Wang W and Liang C: Sodium-glucose CoTransporter-2
inhibitor empagliflozin ameliorates sunitinib-induced cardiac
dysfunction via regulation of AMPK-mTOR signaling pathway-mediated
autophagy. Front Pharmacol. 12:6641812021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Santos-Gallego CG, Requena-Ibanez JA, San
Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E,
Garcia-Ropero A, Sanz J, Hajjar RJ, et al: Empagliflozin
ameliorates adverse left ventricular remodeling in nondiabetic
heart failure by enhancing myocardial energetics. J Am Coll
Cardiol. 73:1931–1944. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yurista SR, Silljé HHW, Oberdorf-Maass SU,
Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van
Veldhuisen DJ, de Boer RA and Westenbrink BD: Sodium-glucose
co-transporter 2 inhibition with empagliflozin improves cardiac
function in non-diabetic rats with left ventricular dysfunction
after myocardial infarction. Eur J Heart Fail. 21:862–873. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Habibi J, Aroor AR, Sowers JR, Jia G,
Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A
and DeMarco VG: Sodium glucose transporter 2 (SGLT2) inhibition
with empagliflozin improves cardiac diastolic function in a female
rodent model of diabetes. Cardiovasc Diabetol. 16:92017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang N, Feng B, Ma X, Sun K, Xu G and
Zhou Y: Dapagliflozin improves left ventricular remodeling and
aorta sympathetic tone in a pig model of heart failure with
preserved ejection fraction. Cardiovasc Diabetol. 18:1072019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee HC, Shiou YL, Jhuo SJ, Chang CY, Liu
PL, Jhuang WJ, Dai ZK, Chen WY, Chen YF and Lee AS: The
sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates
cardiac fibrosis and improves ventricular hemodynamics in
hypertensive heart failure rats. Cardiovasc Diabetol. 18:452019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lahnwong S, Palee S, Apaijai N,
Sriwichaiin S, Kerdphoo S, Jaiwongkam T, Chattipakorn SC and
Chattipakorn N: Acute dapagliflozin administration exerts
cardioprotective effects in rats with cardiac ischemia/reperfusion
injury. Cardiovasc Diabetol. 19:912020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kräker K, Herse F, Golic M, Reichhart N,
Crespo-Garcia S, Strauß O, Grune J, Kintscher U, Ebrahim M, Bader
M, et al: Effects of empagliflozin and target-organ damage in a
novel rodent model of heart failure induced by combined
hypertension and diabetes. Sci Rep. 10:140612020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Santos-Gallego CG, Requena-Ibanez JA, San
Antonio R, Garcia-Ropero A, Ishikawa K, Watanabe S, Picatoste B,
Vargas-Delgado AP, Flores-Umanzor EJ, Sanz J, et al: Empagliflozin
ameliorates diastolic dysfunction and left ventricular
fibrosis/stiffness in nondiabetic heart failure: A multimodality
study. JACC Cardiovasc Imaging. 14:393–407. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lin YW, Chen CY, Shih JY, Cheng BC, Chang
CP, Lin MT, Ho CH, Chen ZC, Fisch S and Chang WT: Dapagliflozin
improves cardiac hemodynamics and mitigates arrhythmogenesis in
mitral regurgitation-induced myocardial dysfunction. J Am Heart
Assoc. 10:e0192742021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dini FL, Galeotti GG, Terlizzese G,
Fabiani I, Pugliese NR and Rovai I: Left ventricular mass and
thickness: Why does it matter? Heart Fail Clin. 15:159–166. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Matsutani D, Sakamoto M, Kayama Y, Takeda
N, Horiuchi R and Utsunomiya K: Effect of canagliflozin on left
ventricular diastolic function in patients with type 2 diabetes.
Cardiovasc Diabetol. 17:732018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nakamura M and Sadoshima J: Mechanisms of
physiological and pathological cardiac hypertrophy. Nat Rev
Cardiol. 15:387–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Querejeta R, López B, González A, Sánchez
E, Larman M, Martínez Ubago JL and Díez J: Increased collagen type
I synthesis in patients with heart failure of hypertensive origin:
Relation to myocardial fibrosis. Circulation. 110:1263–1268. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Frangogiannis NG: Cardiac fibrosis: Cell
biological mechanisms, molecular pathways and therapeutic
opportunities. Mol Aspects Med. 65:70–99. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Frangogiannis NG: Cardiac fibrosis.
Cardiovasc Res. 117:1450–1488. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Travers JG, Tharp CA, Rubino M and
McKinsey TA: Therapeutic targets for cardiac fibrosis: From old
school to next-gen. J Clin Invest. 132:e1485542022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Aluja D, Delgado-Tomás S, Ruiz-Meana M,
Barrabés JA and Inserte J: Calpains as potential therapeutic
targets for myocardial hypertrophy. Int J Mol Sci. 23:41032022.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yerra VG, Batchu SN, Kabir G, Advani SL,
Liu Y, Siddiqi FS, Connelly KA and Advani A: Empagliflozin disrupts
a Tnfrsf12a-mediated feed forward loop that promotes left
ventricular hypertrophy. Cardiovasc Drugs Ther. 36:619–632. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Shi L, Zhu D, Wang S, Jiang A and Li F:
Dapagliflozin attenuates cardiac remodeling in mice model of
cardiac pressure overload. Am J Hypertens. 32:452–459. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li X, Lu Q, Qiu Y, do Carmo JM, Wang Z, da
Silva AA, Mouton A, Omoto ACM, Hall ME, Li J and Hall JE: Direct
Cardiac actions of the sodium glucose co-transporter 2 inhibitor
empagliflozin improve myocardial oxidative phosphorylation and
attenuate pressure-overload heart failure. J Am Heart Assoc.
10:e0182982021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Liu L, Luo H, Liang Y, Tang J and Shu Y:
Dapagliflozin ameliorates STZ-induced cardiac hypertrophy in type 2
diabetic rats by inhibiting the calpain-1 expression and nuclear
transfer of NF-kappaB. Comput Math Methods Med.
2022:32930542022.PubMed/NCBI
|
|
59
|
Wang J, Huang X, Liu H, Chen Y, Li P, Liu
L, Li J, Ren Y, Huang J, Xiong E, et al: Empagliflozin ameliorates
diabetic cardiomyopathy via attenuating oxidative stress and
improving mitochondrial function. Oxid Med Cell Longev.
2022:11224942022.PubMed/NCBI
|
|
60
|
Kimura T, Nakamura K, Miyoshi T, Yoshida
M, Akazawa K, Saito Y, Akagi S, Ohno Y, Kondo M, Miura D, et al:
Inhibitory effects of tofogliflozin on cardiac hypertrophy in dahl
salt-sensitive and salt-resistant rats fed a high-fat diet. Int
Heart J. 60:728–735. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hsieh PL, Chu PM, Cheng HC, Huang YT, Chou
WC, Tsai KL and Chan SH: Dapagliflozin mitigates doxorubicin-caused
myocardium damage by regulating AKT-mediated oxidative stress,
cardiac remodeling, and inflammation. Int J Mol Sci. 23:101462022.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Asensio Lopez MDC, Lax A, Hernandez
Vicente A, Saura Guillen E, Hernandez-Martinez A, Fernandez Del
Palacio MJ, Bayes-Genis A and Pascual Figal DA: Empagliflozin
improves post-infarction cardiac remodeling through GTP enzyme
cyclohydrolase 1 and irrespective of diabetes status. Sci Rep.
10:135532020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Jiang K, Xu Y, Wang D, Chen F, Tu Z, Qian
J, Xu S, Xu Y, Hwa J, Li J, et al: Cardioprotective mechanism of
SGLT2 inhibitor against myocardial infarction is through reduction
of autosis. Protein Cell. 13:336–359. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Crow MT, Mani K, Nam YJ and Kitsis RN: The
mitochondrial death pathway and cardiac myocyte apoptosis. Circ
Res. 95:957–970. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Del Re DP, Amgalan D, Linkermann A, Liu Q
and Kitsis RN: Fundamental mechanisms of regulated cell death and
implications for heart disease. Physiol Rev. 99:1765–1817. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Abbate A, Bussani R, Amin MS, Vetrovec GW
and Baldi A: Acute myocardial infarction and heart failure: Role of
apoptosis. Int J Biochem Cell Biol. 38:1834–1840. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Liu Y, Wu M, Xu J, Xu B and Kang L:
Empagliflozin prevents from early cardiac injury post myocardial
infarction in non-diabetic mice. Eur J Pharm Sci. 161:1057882021.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Long Q, Li L, Yang H, Lu Y, Yang H, Zhu Y,
Tang Y, Liu C and Yuan J: SGLT2 inhibitor, canagliflozin,
ameliorates cardiac inflammation in experimental autoimmune
myocarditis. Int Immunopharmacol. 110:1090242022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
El-Sayed N, Mostafa YM, AboGresha NM,
Ahmed AAM, Mahmoud IZ and El-Sayed NM: Dapagliflozin attenuates
diabetic cardiomyopathy through erythropoietin up-regulation of
AKT/JAK/MAPK pathways in streptozotocin-induced diabetic rats. Chem
Biol Interact. 347:1096172021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Fan ZG, Xu Y, Chen X, Ji MY and Ma GS:
Appropriate dose of dapagliflozin improves cardiac outcomes by
normalizing mitochondrial fission and reducing cardiomyocyte
apoptosis after acute myocardial infarction. Drug Des Devel Ther.
16:2017–2030. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Chang WT, Shih JY, Lin YW, Chen ZC, Kan
WC, Lin TH and Hong CS: Dapagliflozin protects against
doxorubicin-induced cardiotoxicity by restoring STAT3. Arch
Toxicol. 96:2021–2032. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ren FF, Xie ZY, Jiang YN, Guan X, Chen QY,
Lai TF and Li L: Dapagliflozin attenuates pressure overload-induced
myocardial remodeling in mice via activating SIRT1 and inhibiting
endoplasmic reticulum stress. Acta Pharmacol Sin. 43:1721–1732.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zein L, Fulda S, Kögel D and van Wijk SJL:
Organelle-specific mechanisms of drug-induced autophagy-dependent
cell death. Matrix Biol. 100-101:54–64. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhang J, Liu J, Huang Y, Chang JYF, Liu L,
McKeehan WL, Martin JF and Wang F: FRS2α-mediated FGF signals
suppress premature differentiation of cardiac stem cells through
regulating autophagy activity. Circ Res. 110:e29–e39. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Morales PE, Arias-Durán C, Ávalos-Guajardo
Y, Aedo G, Verdejo HE, Parra V and Lavandero S: Emerging role of
mitophagy in cardiovascular physiology and pathology. Mol Aspects
Med. 71:1008222020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Gatica D, Chiong M, Lavandero S and
Klionsky DJ: Molecular mechanisms of autophagy in the
cardiovascular system. Circ Res. 116:456–467. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Nakai A, Yamaguchi O, Takeda T, Higuchi Y,
Hikoso S, Taniike M, Omiya S, Mizote I, Matsumura Y, Asahi M, et
al: The role of autophagy in cardiomyocytes in the basal state and
in response to hemodynamic stress. Nat Med. 13:619–624. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Munasinghe PE, Riu F, Dixit P, Edamatsu M,
Saxena P, Hamer NS, Galvin IF, Bunton RW, Lequeux S, Jones G, et
al: Type-2 diabetes increases autophagy in the human heart through
promotion of Beclin-1 mediated pathway. Int J Cardiol. 202:13–20.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Shirakabe A, Zhai P, Ikeda Y, Saito T,
Maejima Y, Hsu CP, Nomura M, Egashira K, Levine B and Sadoshima J:
Drp1-dependent mitochondrial autophagy plays a protective role
against pressure overload-induced mitochondrial dysfunction and
heart failure. Circulation. 133:1249–1263. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Nishida K and Otsu K: Autophagy during
cardiac remodeling. J Mol Cell Cardiol. 95:11–18. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Nah J, Zhai P, Huang CY, Fernández ÁF,
Mareedu S, Levine B and Sadoshima J: Upregulation of Rubicon
promotes autosis during myocardial ischemia/reperfusion injury. J
Clin Invest. 130:2978–2991. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ikeda S, Zablocki D and Sadoshima J: The
role of autophagy in death of cardiomyocytes. J Mol Cell Cardiol.
165:1–8. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Gatica D, Chiong M, Lavandero S and
Klionsky DJ: The role of autophagy in cardiovascular pathology.
Cardiovasc Res. 118:934–950. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Wang CY, Chen CC, Lin MH, Su HT, Ho MY,
Yeh JK, Tsai ML, Hsieh IC and Wen MS: TLR9 binding to Beclin 1 and
mitochondrial SIRT3 by a sodium-glucose co-transporter 2 inhibitor
protects the heart from doxorubicin toxicity. Biology (Basel).
9:3692020.PubMed/NCBI
|
|
85
|
Deng R, Jiang K, Chen F, Miao Y, Lu Y, Su
F, Liang J, Qian J, Wang D, Xiang Y and Shen L: Novel
cardioprotective mechanism for empagliflozin in nondiabetic
myocardial infarction with acute hyperglycemia. Biomed
Pharmacother. 154:1136062022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kang R, Zeh HJ, Lotze MT and Tang D: The
Beclin 1 network regulates autophagy and apoptosis. Cell Death
Differ. 18:571–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Wang CC, Li Y, Qian XQ, Zhao H, Wang D,
Zuo GX and Wang K: Empagliflozin alleviates myocardial I/R injury
and cardiomyocyte apoptosis via inhibiting ER stress-induced
autophagy and the PERK/ATF4/Beclin1 pathway. J Drug Target.
30:858–872. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Aragón-Herrera A, Feijóo-Bandín S, Otero
Santiago M, Barral L, Campos-Toimil M, Gil-Longo J, Costa Pereira
TM, Garcia-Caballero T, Rodriguez-Segade S, Rodriguez J, et al:
Empagliflozin reduces the levels of CD36 and cardiotoxic lipids
while improving autophagy in the hearts of Zucker diabetic fatty
rats. Biochem Pharmacol. 170:1136772019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Ma H and Ma Y: Dapagliflozin inhibits
ventricular remodeling in heart failure rats by activating
autophagy through AMPK/mTOR pathway. Comput Math Methods Med.
2022:62602022022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Yu YW, Que JQ, Liu S, Huang KY, Qian L,
Weng YB, Rong FN, Wang L, Zhou YY, Xue YJ and Ji KT: Sodium-glucose
co-transporter-2 inhibitor of dapagliflozin attenuates myocardial
ischemia/reperfusion injury by limiting NLRP3 inflammasome
activation and modulating autophagy. Front Cardiovasc Med.
8:7682142022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Qin Y, Qiao Y, Wang D, Tang C and Yan G:
Ferritinophagy and ferroptosis in cardiovascular disease:
Mechanisms and potential applications. Biomed Pharmacother.
141:1118722021. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Tang D, Chen X, Kang R and Kroemer G:
Ferroptosis: molecular mechanisms and health implications. Cell
Res. 31:107–125. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Huang X, Song Y, Wei L, Guo J, Xu W and Li
M: The emerging roles of ferroptosis in organ fibrosis and its
potential therapeutic effect. Int Immunopharmacol. 116:1098122023.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Feng Y, Madungwe NB, Imam Aliagan AD,
Tombo N and Bopassa JC: Liproxstatin-1 protects the mouse
myocardium against ischemia/reperfusion injury by decreasing VDAC1
levels and restoring GPX4 levels. Biochem Biophys Res Commun.
520:606–611. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Fang X, Wang H, Han D, Xie E, Yang X, Wei
J, Gu S, Gao F, Zhu N, Yin X, et al: Ferroptosis as a target for
protection against cardiomyopathy. Proc Natl Acad Sci USA.
116:2672–2680. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Baba Y, Higa JK, Shimada BK, Horiuchi KM,
Suhara T, Kobayashi M, Woo JD, Aoyagi H, Marh KS, Kitaoka H and
Matsui T: Protective effects of the mechanistic target of rapamycin
against excess iron and ferroptosis in cardiomyocytes. Am J Physiol
Heart Circ Physiol. 314:H659–H668. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Bai T, Li M, Liu Y, Qiao Z and Wang Z:
Inhibition of ferroptosis alleviates atherosclerosis through
attenuating lipid peroxidation and endothelial dysfunction in mouse
aortic endothelial cell. Free Radic Biol Med. 160:92–102. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Chen X, Xu S, Zhao C and Liu B: Role of
TLR4/NADPH oxidase 4 pathway in promoting cell death through
autophagy and ferroptosis during heart failure. Biochem Biophys Res
Commun. 516:37–43. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Ma S, He LL, Zhang GR, Zuo QJ, Wang ZL,
Zhai JL, Zhang TT, Wang Y, Ma HJ and Guo YF: Canagliflozin
mitigates ferroptosis and ameliorates heart failure in rats with
preserved ejection fraction. Naunyn Schmiedebergs Arch Pharmacol.
395:945–962. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Wang X, Chen X, Zhou W, Men H, Bao T, Sun
Y, Wang Q, Tan Y, Keller BB, Tong Q, et al: Ferroptosis is
essential for diabetic cardiomyopathy and is prevented by
sulforaphane via AMPK/NRF2 pathways. Acta Pharm Sin B. 12:708–722.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Du S, Shi H, Xiong L, Wang P and Shi Y:
Canagliflozin mitigates ferroptosis and improves myocardial
oxidative stress in mice with diabetic cardiomyopathy. Front
Endocrinol (Lausanne). 13:10116692022. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Zhang W, Lu J, Wang Y, Sun P, Gao T, Xu N,
Zhang Y and Xie W: Canagliflozin attenuates lipotoxicity in
cardiomyocytes by inhibiting inflammation and ferroptosis through
activating AMPK pathway. Int J Mol Sci. 24:8582023. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Min J, Wu L, Liu Y, Song G, Deng Q, Jin W,
Yu W, Abudureyimu M, Pei Z and Ren J: Empagliflozin attenuates
trastuzumab-induced cardiotoxicity through suppression of DNA
damage and ferroptosis. Life Sci. 312:1212072023. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Chen W, Zhang Y, Wang Z, Tan M, Lin J,
Qian X, Li H and Jiang T: Dapagliflozin alleviates myocardial
ischemia/reperfusion injury by reducing ferroptosis via MAPK
signaling inhibition. Front Pharmacol. 14:10782052023. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Aimo A, Castiglione V, Borrelli C, Saccaro
LF, Franzini M, Masi S, Emdin M and Giannoni A: Oxidative stress
and inflammation in the evolution of heart failure: From
pathophysiology to therapeutic strategies. Eur J Prev Cardiol.
27:494–510. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Halade GV and Lee DH: Inflammation and
resolution signaling in cardiac repair and heart failure.
EBioMedicine. 79:1039922022. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Prabhu SD and Frangogiannis NG: The
biological basis for cardiac repair after myocardial infarction:
From inflammation to fibrosis. Circ Res. 119:91–112. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Timmers L, Pasterkamp G, de Hoog VC,
Arslan F, Appelman Y and de Kleijn DPV: The innate immune response
in reperfused myocardium. Cardiovasc Res. 94:276–283. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Schroder K and Tschopp J: The
inflammasomes. Cell. 140:821–832. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Frieler RA and Mortensen RM: Immune cell
and other noncardiomyocyte regulation of cardiac hypertrophy and
remodeling. Circulation. 131:1019–1030. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Haudek SB, Taffet GE, Schneider MD and
Mann DL: TNF provokes cardiomyocyte apoptosis and cardiac
remodeling through activation of multiple cell death pathways. J
Clin Invest. 117:2692–2701. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Ing DJ, Zang J, Dzau VJ, Webster KA and
Bishopric NH: Modulation of cytokine-induced cardiac myocyte
apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res. 84:21–33.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Meléndez GC, McLarty JL, Levick SP, Du Y,
Janicki JS and Brower GL: Interleukin 6 mediates myocardial
fibrosis, concentric hypertrophy, and diastolic dysfunction in
rats. Hypertension. 56:225–231. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Sivasubramanian N, Coker ML, Kurrelmeyer
KM, MacLellan WR, DeMayo FJ, Spinale FG and Mann DL: Left
ventricular remodeling in transgenic mice with cardiac restricted
overexpression of tumor necrosis factor. Circulation. 104:826–831.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Saxena A, Chen W, Su Y, Rai V, Uche OU, Li
N and Frangogiannis NG: IL-1 induces proinflammatory leukocyte
infiltration and regulates fibroblast phenotype in the infarcted
myocardium. J Immunol. 191:4838–4848. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Chou CH, Hung CS, Liao CW, Wei LH, Chen
CW, Shun CT, Wen WF, Wan CH, Wu XM, Chang YY, et al: IL-6
trans-signalling contributes to aldosterone-induced cardiac
fibrosis. Cardiovasc Res. 114:690–702. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Didion SP, Kinzenbaw DA, Schrader LI, Chu
Y and Faraci FM: Endogenous interleukin-10 inhibits angiotensin
II-induced vascular dysfunction. Hypertension. 54:619–624. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Szalay G, Sauter M, Hald J, Weinzierl A,
Kandolf R and Klingel K: Sustained nitric oxide synthesis
contributes to immunopathology in ongoing myocarditis attributable
to interleukin-10 disorders. Am J Pathol. 169:2085–2093. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Kolijn D, Pabel S, Tian Y, Lódi M, Herwig
M, Carrizzo A, Zhazykbayeva S, Kovács A, Fülöp GÁ, Falcão-Pires I,
et al: Empagliflozin improves endothelial and cardiomyocyte
function in human heart failure with preserved ejection fraction
via reduced pro-inflammatory-oxidative pathways and protein kinase
Gα oxidation. Cardiovasc Res. 117:495–507. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Yan P, Song X, Tran J, Zhou R, Cao X, Zhao
G and Yuan H: Dapagliflozin alleviates coxsackievirus B3-induced
acute viral myocarditis by regulating the macrophage polarization
through Stat3-related pathways. Inflammation. 45:2078–2090. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Faridvand Y, Nemati M,
Zamani-Gharehchamani E, Nejabati HR, Zamani ARN, Nozari S, Safaie
N, Nouri M and Jodati A: Dapagliflozin protects H9c2 cells against
injury induced by lipopolysaccharide via suppression of
CX3CL1/CX3CR1 axis and NF-κB activity. Curr Mol Pharmacol.
15:862–869. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Pinar AA, Scott TE, Huuskes BM, Tapia
Cáceres FE, Kemp-Harper BK and Samuel CS: Targeting the NLRP3
inflammasome to treat cardiovascular fibrosis. Pharmacol Ther.
209:1075112020. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Toldo S and Abbate A: The NLRP3
inflammasome in acute myocardial infarction. Nat Rev Cardiol.
15:203–214. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Suetomi T, Willeford A, Brand CS, Cho Y,
Ross RS, Miyamoto S and Brown JH: Inflammation and NLRP3
inflammasome activation initiated in response to pressure overload
by Ca2+/calmodulin-dependent protein kinase II δ
signaling in cardiomyocytes are essential for adverse cardiac
remodeling. Circulation. 138:2530–2544. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Sokolova M, Ranheim T, Louwe MC, Halvorsen
B, Yndestad A and Aukrust P: NLRP3 inflammasome: A novel player in
metabolically induced inflammation-potential influence on the
myocardium. J Cardiovasc Pharmacol. 74:276–284. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Ye Y, Bajaj M, Yang HC, Perez-Polo JR and
Birnbaum Y: SGLT-2 inhibition with dapagliflozin reduces the
activation of the Nlrp3/ASC inflammasome and attenuates the
development of diabetic cardiomyopathy in mice with type 2
diabetes. Further augmentation of the effects with saxagliptin, a
DPP4 inhibitor. Cardiovasc Drugs Ther. 31:119–132. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Chen H, Tran D, Yang HC, Nylander S,
Birnbaum Y and Ye Y: Dapagliflozin and ticagrelor have additive
effects on the attenuation of the activation of the NLRP3
inflammasome and the progression of diabetic cardiomyopathy: An
AMPK-mTOR interplay. Cardiovasc Drugs Ther. 34:443–461. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Quagliariello V, De Laurentiis M, Rea D,
Barbieri A, Monti MG, Carbone A, Paccone A, Altucci L, Conte M,
Canale ML, et al: The SGLT-2 inhibitor empagliflozin improves
myocardial strain, reduces cardiac fibrosis and pro-inflammatory
cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc
Diabetol. 20:1502021. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Hu J, Xu J, Tan X, Li D, Yao D, Xu B and
Lei Y: Dapagliflozin protects against dilated cardiomyopathy
progression by targeting NLRP3 inflammasome activation. Naunyn
Schmiedebergs Arch Pharmacol. 396:1461–1470. 2023.PubMed/NCBI
|
|
130
|
Pullen AB, Jadapalli JK, Rhourri-Frih B
and Halade GV: Re-evaluating the causes and consequences of
non-resolving inflammation in chronic cardiovascular disease. Heart
Fail Rev. 25:381–391. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Lee TM, Chang NC and Lin SZ:
Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac
fibrosis by regulating the macrophage polarization via STAT3
signaling in infarcted rat hearts. Free Radic Biol Med.
104:298–310. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Chelko SP, Asimaki A, Lowenthal J,
Bueno-Beti C, Bedja D, Scalco A, Amat-Alarcon N, Andersen P, Judge
DP, Tung L and Saffitz JE: Therapeutic modulation of the immune
response in arrhythmogenic cardiomyopathy. Circulation.
140:1491–1505. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Yang Z, Li T, Xian J, Chen J, Huang Y,
Zhang Q, Lin X, Lu H and Lin Y: SGLT2 inhibitor dapagliflozin
attenuates cardiac fibrosis and inflammation by reverting the
HIF-2alpha signaling pathway in arrhythmogenic cardiomyopathy.
FASEB J. 36:e224102022. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Salvatore T, Galiero R, Caturano A,
Vetrano E, Rinaldi L, Coviello F, Di Martino A, Albanese G,
Colantuoni S, Medicamento G, et al: Dysregulated epicardial adipose
tissue as a risk factor and potential therapeutic target of heart
failure with preserved ejection fraction in diabetes. Biomolecules.
12:1762022. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Gordon M, Meagher P and Connelly KA:
Effect of empagliflozin and liraglutide on the nucleotide-binding
and oligomerization domain-like receptor family pyrin
domain-containing 3 inflammasome in a rodent model of type 2
diabetes mellitus. Can J Diabetes. 45:553–556. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Michaeloudes C, Abubakar-Waziri H, Lakhdar
R, Raby K, Dixey P, Adcock IM, Mumby S, Bhavsar PK and Chung KF:
Molecular mechanisms of oxidative stress in asthma. Mol Aspects
Med. 85:1010262022. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Weissman D and Maack C: Redox signaling in
heart failure and therapeutic implications. Free Radic Biol Med.
171:345–364. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Zhang M, Perino A, Ghigo A, Hirsch E and
Shah AM: NADPH oxidases in heart failure: Poachers or gamekeepers?
Antioxid Redox Signal. 18:1024–1041. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Burgoyne JR, Mongue-Din H, Eaton P and
Shah AM: Redox signaling in cardiac physiology and pathology. Circ
Res. 111:1091–1106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
van der Pol A, van Gilst WH, Voors AA and
van der Meer P: Treating oxidative stress in heart failure: Past,
present and future. Eur J Heart Fail. 21:425–435. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Li A, Zheng N and Ding X: Mitochondrial
abnormalities: A hub in metabolic syndrome-related cardiac
dysfunction caused by oxidative stress. Heart Fail Rev.
27:1387–1394. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Xing YJ, Liu BH, Wan SJ, Cheng Y, Zhou SM,
Sun Y, Yao XM, Hua Q, Meng XJ, Cheng JH, et al: A SGLT2 inhibitor
dapagliflozin alleviates diabetic cardiomyopathy by suppressing
high glucose-induced oxidative stress in vivo and in vitro. Front
Pharmacol. 12:7081772021. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Li X, Flynn ER, do Carmo JM, Wang Z, da
Silva AA, Mouton AJ, Omoto ACM, Hall ME and Hall JE: Direct cardiac
actions of sodium-glucose cotransporter 2 inhibition improve
mitochondrial function and attenuate oxidative stress in pressure
overload-induced heart failure. Front Cardiovasc Med. 9:8592532022.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Sun X, Han F, Lu Q, Li X, Ren D, Zhang J,
Han Y, Xiang YK and Li J: Empagliflozin ameliorates obesity-related
cardiac dysfunction by regulating sestrin2-mediated AMPK-mTOR
signaling and redox homeostasis in high-fat diet-induced obese
mice. Diabetes. 69:1292–1305. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Bugga P, Mohammed SA, Alam MJ, Katare P,
Meghwani H, Maulik SK, Arava S and Banerjee SK: Empagliflozin
prohibits high-fructose diet-induced cardiac dysfunction in rats
via attenuation of mitochondria-driven oxidative stress. Life Sci.
307:1208622022. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Lopaschuk GD, Ussher JR, Folmes CD, Jaswal
JS and Stanley WC: Myocardial fatty acid metabolism in health and
disease. Physiol Rev. 90:207–258. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Taegtmeyer H, Sen S and Vela D: Return to
the fetal gene program: A suggested metabolic link to gene
expression in the heart. Ann N Y Acad Sci. 1188:191–198. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Ingwall JS: Energy metabolism in heart
failure and remodelling. Cardiovasc Res. 81:412–419. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Rosca MG, Tandler B and Hoppel CL:
Mitochondria in cardiac hypertrophy and heart failure. J Mol Cell
Cardiol. 55:31–41. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Zhang L, Jaswal JS, Ussher JR,
Sankaralingam S, Wagg C, Zaugg M and Lopaschuk GD: Cardiac
insulin-resistance and decreased mitochondrial energy production
precede the development of systolic heart failure after
pressure-overload hypertrophy. Circ Heart Fail. 6:1039–1048. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
De Jong KA and Lopaschuk GD: Complex
energy metabolic changes in heart failure with preserved ejection
fraction and heart failure with reduced ejection fraction. Can J
Cardiol. 33:860–871. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Kolwicz SC Jr, Olson DP, Marney LC,
Garcia-Menendez L, Synovec RE and Tian R: Cardiac-specific deletion
of acetyl CoA carboxylase 2 prevents metabolic remodeling during
pressure-overload hypertrophy. Circ Res. 111:728–738. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Choi YS, de Mattos ABM, Shao D, Li T,
Nabben M, Kim M, Wang W, Tian R and Kolwicz SC Jr: Preservation of
myocardial fatty acid oxidation prevents diastolic dysfunction in
mice subjected to angiotensin II infusion. J Mol Cell Cardiol.
100:64–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Chess DJ, Lei B, Hoit BD, Azimzadeh AM and
Stanley WC: Effects of a high saturated fat diet on cardiac
hypertrophy and dysfunction in response to pressure overload. J
Card Fail. 14:82–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Trang NN, Chung CC, Lee TW, Cheng WL, Kao
YH, Huang SY, Lee TI and Chen YJ: Empagliflozin and liraglutide
differentially modulate cardiac metabolism in diabetic
cardiomyopathy in rats. Int J Mol Sci. 22:11772021. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Jia G, DeMarco VG and Sowers JR: Insulin
resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat
Rev Endocrinol. 12:144–153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Lai J and Chen C: The role of
epoxyeicosatrienoic acids in cardiac remodeling. Front Physiol.
12:6424702021. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Shi W, Xin Q, Yuan R, Yuan Y, Cong W and
Chen K: Neovascularization: The main mechanism of MSCs in ischemic
heart disease therapy. Front Cardiovasc Med. 8:6333002021.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Shu HY, Peng YZ, Hang WJ, Zhang M, Shen L,
Wang DW and Zhou N: Trimetazidine enhances myocardial angiogenesis
in pressure overload-induced cardiac hypertrophy mice through
directly activating Akt and promoting the binding of HSF1 to VEGF-A
promoter. Acta Pharmacol Sin. 43:2550–2561. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Ni Y, Deng J, Bai H, Liu C, Liu X and Wang
X: CaMKII inhibitor KN-93 impaired angiogenesis and aggravated
cardiac remodelling and heart failure via inhibiting
NOX2/mtROS/p-VEGFR2 and STAT3 pathways. J Cell Mol Med. 26:312–325.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Blom JN, Wang X, Lu X, Kim MY, Wang G and
Feng Q: Inhibition of intraflagellar transport protein-88 promotes
epithelial-to-mesenchymal transition and reduces cardiac remodeling
post-myocardial infarction. Eur J Pharmacol. 933:1752872022.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Wei T, Huang G, Gao J, Huang C, Sun M, Wu
J, Bu J and Shen W: Sirtuin 3 deficiency accelerates hypertensive
cardiac remodeling by impairing angiogenesis. J Am Heart Assoc.
6:e0061142017. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Gogiraju R, Hubert A, Fahrer J, Straub BK,
Brandt M, Wenzel P, Münzel T, Konstantinides S, Hasenfuss G and
Schäfer K: Endothelial leptin receptor deletion promotes cardiac
autophagy and angiogenesis following pressure overload by
suppressing Akt/mTOR signaling. Circ Heart Fail. 12:e0056222019.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Gu J, Wang S, Guo H, Tan Y, Liang Y, Feng
A, Liu Q, Damodaran C, Zhang Z, Keller BB, et al: Inhibition of p53
prevents diabetic cardiomyopathy by preventing early-stage
apoptosis and cell senescence, reduced glycolysis, and impaired
angiogenesis. Cell Death Dis. 9:822018. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Zhou H, Wang S, Zhu P, Hu S, Chen Y and
Ren J: Empagliflozin rescues diabetic myocardial microvascular
injury via AMPK-mediated inhibition of mitochondrial fission. Redox
Biol. 15:335–346. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Nugrahaningrum DA, Marcelina O, Liu C, Wu
S and Kasim V: Dapagliflozin promotes neovascularization by
improving paracrine function of skeletal muscle cells in diabetic
hindlimb ischemia mice through PHD2/HIF-1α axis. Front Pharmacol.
11:11042020. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Nakao M, Shimizu I, Katsuumi G, Yoshida Y,
Suda M, Hayashi Y, Ikegami R, Hsiao YT, Okuda S, Soga T and
Minamino T: Empagliflozin maintains capillarization and improves
cardiac function in a murine model of left ventricular pressure
overload. Sci Rep. 11:183842021. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Zou R, Shi W, Qiu J, Zhou N, Du N, Zhou H,
Chen X and Ma L: Empagliflozin attenuates cardiac microvascular
ischemia/reperfusion injury through improving mitochondrial
homeostasis. Cardiovasc Diabetol. 21:1062022. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Ma L, Zou R, Shi W, Zhou N, Chen S, Zhou
H, Chen X and Wu Y: SGLT2 inhibitor dapagliflozin reduces
endothelial dysfunction and microvascular damage during cardiac
ischemia/reperfusion injury through normalizing the
XO-SERCA2-CaMKII-coffilin pathways. Theranostics. 12:5034–5050.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Guo H, Yu X, Liu Y, Paik DT, Justesen JM,
Chandy M, Jahng JWS, Zhang T, Wu W, Rwere F, et al: SGLT2 inhibitor
ameliorates endothelial dysfunction associated with the common
ALDH2 alcohol flushing variant. Sci Transl Med. 15:eabp99522023.
View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Cai C, Guo Z, Chang X, Li Z, Wu F, He J,
Cao T, Wang K, Shi N, Zhou H, et al: Empagliflozin attenuates
cardiac microvascular ischemia/reperfusion through activating the
AMPKalpha1/ULK1/FUNDC1/mitophagy pathway. Redox Biol.
52:1022882022. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Hanna A and Frangogiannis NG: The role of
the TGF-beta superfamily in myocardial infarction. Front Cardiovasc
Med. 6:1402019. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Tarbit E, Singh I, Peart JN and Rose'Meyer
RB: Biomarkers for the identification of cardiac fibroblast and
myofibroblast cells. Heart Fail Rev. 24:1–15. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Li C, Zhang J, Xue M, Li X, Han F, Liu X,
Xu L, Lu Y, Cheng Y, Li T, et al: SGLT2 inhibition with
empagliflozin attenuates myocardial oxidative stress and fibrosis
in diabetic mice heart. Cardiovasc Diabetol. 18:152019. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Humeres C, Shinde AV, Hanna A, Alex L,
Hernández SC, Li R, Chen B, Conway SJ and Frangogiannis NG: Smad7
effects on TGF-β and ErbB2 restrain myofibroblast activation and
protect from postinfarction heart failure. J Clin Invest.
132:e1469262022. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Daud E, Ertracht O, Bandel N, Moady G,
Shehadeh M, Reuveni T and Atar S: The impact of empagliflozin on
cardiac physiology and fibrosis early after myocardial infarction
in non-diabetic rats. Cardiovasc Diabetol. 20:1322021. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Zhang Y, Lin X, Chu Y, Chen X, Du H, Zhang
H, Xu C, Xie H, Ruan Q, Lin J, et al: Dapagliflozin: a
sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin
II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad
signaling. Cardiovasc Diabetol. 20:1212021. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Qi H, Liu Y, Li S, Chen Y, Li L, Cao Y, E
M, Shi P, Song C, Li B and Sun H: Activation of AMPK attenuated
cardiac fibrosis by inhibiting CDK2 via p21/p27 and miR-29 family
pathways in rats. Mol Ther Nucleic Acids. 8:277–290. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Hinson JT, Chopra A, Lowe A, Sheng CC,
Gupta RM, Kuppusamy R, O'Sullivan J, Rowe G, Wakimoto H, Gorham J,
et al: Integrative analysis of PRKAG2 cardiomyopathy iPS and
microtissue models identifies AMPK as a regulator of metabolism,
survival, and fibrosis. Cell Rep. 17:3292–3304. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Tian J, Zhang M, Suo M, Liu D, Wang X, Liu
M, Pan J, Jin T and An F: Dapagliflozin alleviates cardiac fibrosis
through suppressing EndMT and fibroblast activation via
AMPKα/TGF-β/Smad signalling in type 2 diabetic rats. J Cell Mol
Med. 25:7642–7659. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Chen X, Yang Q, Bai W, Yao W, Liu L, Xing
Y, Meng C, Qi P, Dang Y and Qi X: Dapagliflozin attenuates
myocardial fibrosis by inhibiting the TGF-β1/Smad signaling pathway
in a normoglycemic rabbit model of chronic heart failure. Front
Pharmacol. 13:8731082022. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Hepworth EMW and Hinton SD:
Pseudophosphatases as regulators of MAPK signaling. Int J Mol Sci.
22:125952021. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Rose BA, Force T and Wang Y:
Mitogen-activated protein kinase signaling in the heart: Angels
versus demons in a heart-breaking tale. Physiol Rev. 90:1507–1546.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Xu Z, Sun J, Tong Q, Lin Q, Qian L, Park Y
and Zheng Y: The role of ERK1/2 in the development of diabetic
cardiomyopathy. Int J Mol Sci. 17:20012016. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Zhang Q, Wang L, Wang S, Cheng H, Xu L,
Pei G, Wang Y, Fu C, Jiang Y, He C and Wei Q: Signaling pathways
and targeted therapy for myocardial infarction. Signal Transduct
Target Ther. 7:782022. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Pearson G, Robinson F, Beers Gibson T, Xu
BE, Karandikar M, Berman K and Cobb MH: Mitogen-activated protein
(MAP) kinase pathways: Regulation and physiological functions.
Endocr Rev. 22:153–183. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Streicher JM, Ren S, Herschman H and Wang
Y: MAPK-activated protein kinase-2 in cardiac hypertrophy and
cyclooxygenase-2 regulation in heart. Circ Res. 106:1434–1443.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Liu X, Chen K, Zhuang Y, Huang Y, Sui Y,
Zhang Y, Lv L and Zhang G: Paeoniflorin improves pressure
overload-induced cardiac remodeling by modulating the MAPK
signaling pathway in spontaneously hypertensive rats. Biomed
Pharmacother. 111:695–704. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Ren J, Zhang S, Kovacs A, Wang Y and
Muslin AJ: Role of p38alpha MAPK in cardiac apoptosis and
remodeling after myocardial infarction. J Mol Cell Cardiol.
38:617–623. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Yang N, Zou C, Luo W, Xu D, Wang M, Wang
Y, Wu G, Shan P and Liang G: Sclareol attenuates angiotensin
II-induced cardiac remodeling and inflammation via inhibiting MAPK
signaling. Phytother Res. 37:578–591. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Lin K, Yang N, Luo W, Qian JF, Zhu WW, Ye
SJ, Yuan CX, Xu DY, Liang G, Huang WJ and Shan PR: Direct
cardio-protection of dapagliflozin against obesity-related
cardiomyopathy via NHE1/MAPK signaling. Acta Pharmacol Sin.
43:2624–2635. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Yang H, Rudge DG, Koos JD, Vaidialingam B,
Yang HJ and Pavletich NP: mTOR kinase structure, mechanism and
regulation. Nature. 497:217–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Saxton RA and Sabatini DM: mTOR signaling
in growth, metabolism, and disease. Cell. 169:361–371. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Gangloff YG, Mueller M, Dann SG, Svoboda
P, Sticker M, Spetz JF, Um SH, Brown EJ, Cereghini S, Thomas G and
Kozma SC: Disruption of the mouse mTOR gene leads to early
postimplantation lethality and prohibits embryonic stem cell
development. Mol Cell Biol. 24:9508–9516. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Murakami M, Ichisaka T, Maeda M, Oshiro N,
Hara K, Edenhofer F, Kiyama H, Yonezawa K and Yamanaka S: mTOR is
essential for growth and proliferation in early mouse embryos and
embryonic stem cells. Mol Cell Biol. 24:6710–6718. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Shioi T, McMullen JR, Tarnavski O,
Converso K, Sherwood MC, Manning WJ and Izumo S: Rapamycin
attenuates load-induced cardiac hypertrophy in mice. Circulation.
107:1664–1670. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Das A, Salloum FN, Filippone SM, Durrant
DE, Rokosh G, Bolli R and Kukreja RC: Inhibition of mammalian
target of rapamycin protects against reperfusion injury in diabetic
heart through STAT3 signaling. Basic Res Cardiol. 110:312015.
View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Zhao X, Lu S, Nie J, Hu X, Luo W, Wu X,
Liu H, Feng Q, Chang Z, Liu Y, et al: Phosphoinositide-dependent
kinase 1 and mTORC2 synergistically maintain postnatal heart growth
and heart function in mice. Mol Cell Biol. 34:1966–1975. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Xia Y, Wen HY, Young ME, Guthrie PH,
Taegtmeyer H and Kellems RE: Mammalian target of rapamycin and
protein kinase A signaling mediate the cardiac transcriptional
response to glutamine. J Biol Chem. 278:13143–13150. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Sciarretta S, Volpe M and Sadoshima J:
Mammalian target of rapamycin signaling in cardiac physiology and
disease. Circ Res. 114:549–564. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Moellmann J, Mann PA, Kappel BA, Kahles F,
Klinkhammer BM, Boor P, Kramann R, Ghesquiere B, Lebherz C, Marx N
and Lehrke M: The sodium-glucose co-transporter-2 inhibitor
ertugliflozin modifies the signature of cardiac substrate
metabolism and reduces cardiac mTOR signalling, endoplasmic
reticulum stress and apoptosis. Diabetes Obes Metab. 24:2263–2272.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Sciarretta S, Forte M, Frati G and
Sadoshima J: New insights into the role of mTOR signaling in the
cardiovascular system. Circ Res. 122:489–505. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Kim J, Kundu M, Viollet B and Guan KL:
AMPK and mTOR regulate autophagy through direct phosphorylation of
Ulk1. Nat Cell Biol. 13:132–141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Chen L, Liu P, Feng X and Ma C:
Salidroside suppressing LPS-induced myocardial injury by inhibiting
ROS-mediated PI3K/Akt/mTOR pathway in vitro and in vivo. J Cell Mol
Med. 21:3178–3189. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Sun P, Wang Y, Ding Y, Luo J, Zhong J, Xu
N, Zhang Y and Xie W: Canagliflozin attenuates lipotoxicity in
cardiomyocytes and protects diabetic mouse hearts by inhibiting the
mTOR/HIF-1α pathway. iScience. 24:1025212021. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Das S, Aiba T, Rosenberg M, Hessler K,
Xiao C, Quintero PA, Ottaviano FG, Knight AC, Graham EL, Bostrom P,
et al: Pathological role of serum- and glucocorticoid-regulated
kinase 1 in adverse ventricular remodeling. Circulation.
126:2208–2219. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Lang F and Shumilina E: Regulation of ion
channels by the serum- and glucocorticoid-inducible kinase SGK1.
FASEB J. 27:3–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Lee SG, Kim D, Lee JJ, Lee HJ, Moon RK,
Lee YJ, Lee SJ, Lee OH, Kim C, Oh J, et al: Dapagliflozin
attenuates diabetes-induced diastolic dysfunction and cardiac
fibrosis by regulating SGK1 signaling. BMC Med. 20:3092022.
View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Mascareno E, El-Shafei M, Maulik N, Sato
M, Guo Y, Das DK and Siddiqui MA: JAK/STAT signaling is associated
with cardiac dysfunction during ischemia and reperfusion.
Circulation. 104:325–329. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Chakraborty D, Šumová B, Mallano T, Chen
CW, Distler A, Bergmann C, Ludolph I, Horch RE, Gelse K, Ramming A,
et al: Activation of STAT3 integrates common profibrotic pathways
to promote fibroblast activation and tissue fibrosis. Nat Commun.
8:11302017. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Sabe SA, Xu CM, Sabra M, Harris DD,
Malhotra A, Aboulgheit A, Stanley M, Abid MR and Sellke FW:
Canagliflozin improves myocardial perfusion, fibrosis, and function
in a swine model of chronic myocardial ischemia. J Am Heart Assoc.
12:e0286232023. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Yu LM, Di WC, Dong X, Li Z, Zhang Y, Xue
XD, Xu YL, Zhang J, Xiao X, Han JS, et al: Melatonin protects
diabetic heart against ischemia-reperfusion injury, role of
membrane receptor-dependent cGMP-PKG activation. Biochim Biophys
Acta Mol Basis Dis. 1864:563–578. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Mátyás C, Németh BT, Oláh A, Hidi L,
Birtalan E, Kellermayer D, Ruppert M, Korkmaz-Icöz S, Kökény G,
Horváth EM, et al: The soluble guanylate cyclase activator
cinaciguat prevents cardiac dysfunction in a rat model of type-1
diabetes mellitus. Cardiovasc Diabetol. 14:1452015. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Xue M, Li T, Wang Y, Chang Y, Cheng Y, Lu
Y, Liu X, Xu L, Li X, Yu X, et al: Empagliflozin prevents
cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice.
Clin Sci (Lond). 133:1705–1720. 2019. View Article : Google Scholar : PubMed/NCBI
|
